World Class Contributors

6 Six big topics

  1. 50 years of Cambridge Phenomenon history
  2. The inside track on trends in IT and Biosciences
  3. The opportunities made possible by convergence
  4. The secrets of funding
  5. Networking with partners, customers and investors
  6. The future of the Cambridge Phenomenon

We invited a group of internationally renowned speakers and panelists with strong opinions and unrivalled track records. Contributors to The Future Starts Here: the Cambridge Phenomenon 50th Anniversary Conference included entrepreneurs, venture capitalists, financiers, academics, policy makers, futurologists, founders, CEOs and cluster specialists — all are proven in their areas of expertise and many have made significant contributions to the success of the Cambridge Phenomenon. Click on a Watch link to check out videos of all of the inspirational presentations, frank discussions and challenging debates that took place on the day.


Julie Meyer (Conference MC)

Ariadne Capital LinkedIn Watch

Julie Meyer is an American-born entrepreneur, investor, business adviser, networking expert, broadcaster and business commentator. Having worked in the investment and business advisory world for more than 20 years, Julie is the founder and Chief Executive of Ariadne Capital and the Managing Partner of Ariadne Capital Entrepreneurs Fund (ACE). Full profile

She is the founder of Entrepreneur Country and was the co-founder of First Tuesday - the networking forum for start-up technology businesses across Europe – sold in July 2000 to Yazam, a subsidiary of Jerusalem Global, for $50 million.

Meyer is also one of the two dragons on the BBC’s Dragons' Den online and is a regular columnist for the free London business newspaper, City A.M. and regularly contributes to The Daily Telegraph’ business pages.

Julie has appeared as a general business commentator on the BBC (on shows including Newsnight and BBC news online and CNBC as well as contributing to publications such as Bloomberg Businessweek and Spectator Business.

She has won awards including the World Economic Forum Global Leader of Tomorrow, the Ernst & Young Entrepreneur of the Year (October 2000) and a place in the Wall Street Journal’s 30 most influential women in Europe. She was also cited as one of INSEAD’s ‘50 alumni who have changed the world’(2010).

Julie has lived in Europe since 1989.

Sir Leszek Borysiewicz

Medical Research Council Watch

Vice-Chancellor Designate of the University of Cambridge and Chief Executive of the Medical Research Council, Sir Leszek Borysiewicz was knighted in 2001 for his research into developing vaccines. Full profile

Sir Leszek Borysiewicz PhD, FRCP, FRCPath, FMedSci, was appointed Chief Executive of the MRC in October 2007.

Prior to joining the MRC, Sir Leszek was Deputy Rector at Imperial College London, having joined in 2001 as Principal of the Faculty of Medicine. In his latter role at Imperial, Sir Leszek was responsible for the overall academic and scientific direction of the college, particularly the development of inter-disciplinary research between engineering, physical sciences and biomedicine. During his time at Imperial, Sir Leszek was also Governor of the Wellcome Trust (2006-2007), Chairman of the UKCRC Integrated Academic Training Awards Panel (2005–2007), and he continues to Chair the HEFCE RAE Main Panel A Assessment Panel.

Sir Leszek was knighted in the 2001 New Year’s Honours List for his research into developing vaccines, including a vaccine to prevent the development of cervical cancer.

He was a founding Fellow of the Academy of Medical Sciences in 1996 and a member of the AMS Council from 1997 until 2002, Chairman of the NHS (Wales) R&D Grants Committee and acting Director of NHS (Wales) Research and Development (1994-1996), a member of the Council of Cancer Research UK (2002-2005), a Non-Executive Director of North Thames Regional Health Authority (2003-2004) and a member of the MRC Council from 1995 to 2000. He was elected a Fellow of the Royal Society in 2008.

Sir Leszek’s current commitments include membership of the Singapore Biomedical Sciences International Advisory Council; the Health Innovation Council; the Global Science and Innovation Forum; and Chairmanship of the UK Stem Cell Funder’s Forum; the International Stem Cell Forum and the Heads of (Biomedical) Research Organisations. Sir Leszek is also a member of the Lister Institute.

As a physician, Sir Leszek specialises in viral immunology, infectious diseases, cell mediated immunity, virus associated malignancy and vaccine development. He is the author of reports for the World Health Organization, the MRC and the Department of Health, and was Chair of the Department of Health / Medical Research Council TSE Research Advisory Group that reviewed research and coordinated the human health research strategy on Creutzfeldt-Jakob Disease.

Sir Leszek is a Fellow of Cardiff University, the City and Guilds of London Institute and an Honorary Fellow of Wolfson College, Cambridge. He was awarded the Royal Society of Medicine’s Jephcott Medal in 2007, and is a Trustee of the Nuffield Trust.

From October 2010 Sir Leszek will be Vice-Chancellor of the University of Cambridge.

Lord Broers

House of Lords Watch

A nanotechnology pioneer, Alec Broers is convinced that creative engineering is determining the future of the human race and is dedicated to helping people bring their ideas to the marketplace. Full profile

Lord Broers was educated at Melbourne University where he took a BSc in Physics and Electronics, graduating in 1962, and at the same time pursued a semi-professional career as a singer. He gained a BA in mechanical sciences and a PhD and ScD in electrical engineering at Cambridge, working on scanning electron microscopes with Professor Oatley and later with Dr William Nixon. He moved to New York to join IBM's research laboratories, and stayed there for 20 years, becoming one of IBM's most distinguished researchers and being appointed an IBM Fellow in 1977. He returned to Cambridge in 1984 as a Fellow of Trinity College and to take up the Chair of Electrical Engineering, a move that brought the University's Engineering Department to the forefront of nanotechnology research. After a period as Head of the Engineering Department and as Master of Churchill College, he was appointed Vice-Chancellor, the first engineer to hold the post at Cambridge. He co-founded the Cambridge Network with David Cleevely and Hermann Hauser.

His knowledge of and involvement with Cambridge's cluster of hi-tech companies and his encouragement of entrepreneurialism in the University has influenced an increasing number of academics to consider spinning out companies. His championship of the Cambridge-MIT Institute, and many other important initiatives, has changed the culture of the University permanently to create a genuinely entrepreneurial environment with excellent links to local hi-tech business, to sources of funding and to appropriate support for would-be business founders. He was President of the Royal Academy of Engineering from 2001 until 2006, was granted a Peerage in 2004 and in the same year became Chairman of the House of Lords Science and Technology Select Committee. He served many years on the boards of Vodafone, Lucas Industries and Plastic Logic and is currently chairman of the Diamond Light Source Ltd and Bio Nano Consulting and a non-executive director of R J Mears LLC. He delivered the 2005 series of BBC Reith lectures on The Triumph of Technology.

Deborah Cadman

EEDA Watch

Deborah Cadman is chief executive of EEDA. Previously, she enjoyed varied roles in local government, with economic development, environment, corporate policy, social policy and urban regeneration among her specialisms. Full profile

Deborah Cadman became chief executive of EEDA in July 2008.

Deborah gained her first degree in politics and started her career in the engineering department of the London Borough of Newham. Her next post took her to Birmingham, where she spent two years managing a voluntary sector project in Handsworth. Here, she developed partnerships and community strategies and gained a clear appreciation of neighbourhoods.

After joining Birmingham City Council as an economic development officer, Deborah worked on some of the biggest urban regeneration projects in the country. During this period she also worked on major policy projects and public and private sector ventures while gaining a masters degree in economics.

As head of corporate policy at Redcar and Cleveland Borough, Deborah was responsible for regeneration, social policy, partnerships and 'best value'. She was also a member of the National Charities Lotteries Board Advisory Committee in the North East. During this time she gained a second masters degree in management.

Deborah then transferred to central government on secondment. While at the Department of the Environment, Transport and the Regions in its modernisation team, Deborah worked with senior civil servants on local government legislation, advised ministers and provided direct support to councils in the East of England on the modernisation agenda.

A move to the Audit Commission left Deborah responsible for inspections in the London region and management of corporate governance inspections in Walsall, Enfield and Hackney, working with local government to develop sustainable improvement plans.

Deborah held the post of chief executive of St Edmundsbury Borough Council, which gained 'excellent' performing status in 2007, and was also interim chief executive of Waveney District Council between January and March 2008.

She was awarded an OBE in 2006 for services to local government.

David Cleevely

University of Cambridge

David Cleevely cannot resist a challenge. He has started and sold three businesses in telecoms and biotech and has three more on the go, including an award-winning restaurant, but his biggest challenge is helping Cambridge University put science into government policy. Full profile

David Cleevely is an entrepreneur and business angel who has founded a series of companies and acted as government advisor.

He is Chairman of CRFS, the spectrum monitoring company, which he co-founded in July 2007, and the founder and former Chairman of telecoms consultancy Analysys (acquired by Datatec International in 2004). His business and internet expertise were central to the formation of Abcam (ABC.L), which he co-founded in 1998. In late 2004 he co-founded the 3G pico base station company, 3WayNetworks, which was sold to Airvana in April 2007. He joined the Board of Trutap (formerly Hotxt) - a mobile phone social networking provider in October 2005 and joined the Board of ionscope in 2007 and became Chairman in May 2008.

He was a prime mover behind Cambridge Network, co-founder of Cambridge Wireless, co-founder and member of the board of Cambridge Angels and is a member of the IET Telecoms Sector Panel. For eight years until March 2009, David was a member of the Ofcom Spectrum Advisory Board. He held an Industrial Fellowship at the University of Cambridge Computer Laboratory and has recently taken up the post of Founding Director of the Centre for Science and Policy at the University of Cambridge.

Charles Cotton

Cambridge Phenomenon LinkedIn Watch

Charles Cotton is Founder and Chairman of Cambridge Phenomenon Ltd, the organisation behind this conference. Full profile

Charles Cotton is an experienced director of public companies listed on the London, Nasdaq, Euronext Amsterdam, and Frankfurt stock exchanges and private companies in the USA and Europe.

During his career he has lived and worked in the UK, USA and Germany and has experience conducting business in Europe, the Middle East, Asia, North America and Africa. He has advised the UK government on the development of entrepreneurial businesses and the commercialization of science and technology. In addition, he is an adviser to and investor in venture capital firms, an angel investor and mentor.

He is a director of Solarflare, the semiconductor company; Veebeam, the consumer electronics company; and two other companies in California. His UK directorships include Cambridge Phenomenon Ltd, semiconductor company XMOS and Cambridge Enterprise Ltd the organization within the University of Cambridge responsible for spin-outs, licensing and consulting activities.

Prior to its acquisition by TomTom, in June 2008, he was a Supervisory Board member of Tele Atlas, the Euronext Amsterdam and Frankfurt Exchange listed supplier of digital maps. Previously, he was Executive Chairman of GlobespanVirata Inc. the NASDAQ listed, New Jersey based, semiconductor company. Before the merger with GlobeSpan, he was CEO of Virata which he took public on NASDAQ in 1999 to became one of Cambridge’s $Billion companies. He completed five acquisitions and established and ran a venture fund.

Previously, he was CEO of Shandwick Europe; President of Boston Mass. based Thermal Scientific Inc, and a Director of London Stock Exchange listed Thermal Scientific Ltd. Prior to that he was Sales and Marketing Director at Sinclair Research Ltd. and held senior Operations, Finance, Marketing and Product Planning positions at British Leyland and Ford.

He has a BA Hons in Physics from Oxford University and is a Fellow of the Institute of Physics and a Fellow of the Royal Society of Arts.

Sherry Coutu

Director, CEO, Entrepreneur & Investor LinkedIn Watch

Sherry Coutu is an experienced executive, former CEO and angel investor who now serves on the boards of companies, charities and universities. She loves working with great entrepreneurs to solve problems that matter and specialises in consumer internet, information services and clean energy. Full profile

Sherry Coutu is an experienced executive, former CEO and angel investor who now serves on the boards of companies, charities and universities. She loves working with great entrepreneurs to solve problems that matter and specialises in consumer internet, information services and clean energy.

As an entrepreneur, Sherry Coutu established two businesses in the financial services industry. The first (acquired by Euromoney plc) has operations in more than 70 countries. The second was floated in 2000 on London and NASDAQ and was valued at more than $1 billion before being acquired (by AMP plc). Sherry is active in early stage investing and has raised several rounds of venture capital and public equity totalling more than $200 million. The companies she serves range from fast growth private early stage to public and boards with turnover of more than £1billion.

Sherry has been a finalist for both Ernst & Young’s Entrepreneur of the Year and Veuve Cliquot’s Businesswoman of the Year, and was named by Tornado Insider as one of the top 20 trend setting women in Europe. Rated as one of Wired UK’s top 100 power brokers and as one of the top ten female power brokers in the UK, she is a frequent public speaker, a national judge for the Ernst & Young Entrepreneur of the Year awards, and presents regularly at the top business schools.

Current university affiliations include Cambridge University and Harvard Business School. Charitable and Government affiliations include the Prince's Trust, Cancer Research UK and NESTA.

Clive Dix

Modern Biosciences plc Watch

If you want to attract the attention of drug discovery and development expert Clive Dix, include the word Powder in your company name and you might just do it. With successful track-records at both PowderMed Ltd and PowderJect, Clive is now one of the UK’s most respected Bio-Pharma Non-Executive Directors. Full profile

live Dix has more than 20 years' experience in life science research, with over 15 years in senior pharmaceutical industry positions, and a degree and PhD in Pharmacology. His expertise includes an in-depth understanding of all facets of drug discovery and development, a broad knowledge of the science and commercial landscape of a variety of therapeutic areas, and solid experience of the pharmaceutical business and finance community supporting the sector.

Clive was previously co-founder and Chief Executive of PowderMed Ltd, a vaccines development company acquired by Pfizer in November 2006; and before that he was Senior Vice President, Research and Development and a Board member of PowderJect Pharmaceuticals plc until its acquisition by Chiron Vaccines in 2003. Clive began his career in industry at Ciba-Geigy and then GlaxoWellcome, where he left as UK Research Director in 2001. Clive is a recent past Chairman of the BioIndustry Association (BIA) and currently Non-Executive Chairman of Modern Biosciences plc and Crescendo Biologics Ltd.

Warren East

Arm Holdings LinkedIn Watch

Warren East is the CEO of ARM Holdings, one of the most important semiconductor companies in the world. The company has now shipped more processor cores than there are people on the planet. Full profile

Design Engineer on the design of oscillator subsystems for VDUs, RF Emissions measurements and standards compliance.

He moved to Texas Instruments (Semiconductors) in 1983, where he worked on applications and chip design for Microcontrollers, analog telephone devices and Local Area Networks. Contributions included the design of very low power dialer chips, low system cost integrated analog voice circuits, PC modems and LAN adapter system designs. Later he took up responsibility for the marketing of TI’s FPGA devices in Europe.

In 1994, Warren joined ARM (Microprocessor IP) as General Manager of the Design Consulting Business Unit, and subsequently led the creation of ARM’s Development Tools Business Unit. When ARM became a public company in 1998 he took up the role of Vice President of Operations and later Chief Operating Officer before becoming Chief Executive Officer of ARM in 2001.

Over the last six years, ARM has matured into the world’s leading semiconductor IP licensing company, with over 600 microprocessor licenses sold to 200 semiconductor companies worldwide. With annual revenues of approximately $500 million, ARM has 1700 staff and a market capitalization of approximately £2 billion.

Warren East was educated at Monmouth School, Oxford University, where he studied Engineering Science, and Cranfield University, where he did an MBA. He is a Companion of the Chartered Management Institute, a Fellow of the Institute of Engineering and Technology, and a Fellow of the Royal Academy of Engineering. He is a non-executive director of Reciva Limited and Chairman of the Audit Committee for De La Rue plc.

Sir Christopher Evans

Excalibur Group Watch

At the age of ten, Sir Christopher Evans was experimenting with explosives and feeding tadpoles with Lucozade in the dark. Nowadays, Britain’s most successful and controversial biotech entrepreneur and investor is still fighting hard to manoeuvre the UK into pole position on the global bioscience grid. Full profile

A leader in the biotech industry, Sir Christopher is one of Europe’s most successful entrepreneurs. During his career he has established over 50 medical science companies developing over 200 new medicines and built companies worth over £3 billion from scratch. He has successfully floated 20 of these businesses on 5 different stock exchanges around the world. Unsurprisingly, he was twice elected Cambridge Businessman of the Year and has also been Financial Times/Cartier Venturer of the Year. In 2005, he was voted Welsh Business Achiever of the Year and was the youngest ever recipient of the SCI Medal.

Originally from Port Talbot, he gained a degree in microbiology at Imperial College London and a PhD in biochemistry at Porton Down and University of Hull. He did a Research Fellowship at the University of Michigan. He holds professorships and fellowships at over a dozen universities around the UK and has been awarded several Doctor of Science (DSc) degrees. He holds more than 100 publications and patents on his scientific work.

He has founded many of the UK’s most successful biotech companies, including Chiroscience plc, Celsis plc, Ark plc, Vectura plc, Plethora plc, Neuropharm plc, Piramed and Lab21. Sir Christopher is the Founder and Chairman of Merlin Biosciences and Excalibur Group, one of Europe’s largest venture capital firms specialising in medical sciences. Awarded the OBE in 1995 and knighted in 2001, he has collected many medals and awards for his achievements. He was also founded the UK Stem Cell Foundation charity and is a massive Welsh rugby supporter.

Gareth Goodier

Cambridge University Hospitals NHS Foundation Trust Watch

Gareth qualified as a medical practitioner in 1974 and practiced as a clinician in the UK, Australia and Saudi Arabia before moving into management. He has also worked as a management consultant for the World Bank and Arthur Andersen. Full profile

Dr Goodier qualified as a medical practitioner in 1974. He practiced as a clinician in the UK, Australia and Saudi Arabia before moving into management.

He has twelve years experience as the Chief Executive of Academic Teaching Hospitals and seven years as the Chief Executive of Regions or Health Authorities.

He has also worked as a management consultant for the World Bank and Arthur Andersen.

Dr Goodier Co-Authored a Masters course on Quality in Health Care and has lectured in several universities on leadership and contemporary health management.

Dr Goodier has a Masters in Health Management and specialist qualifications in Public Health and Medical Management.

In 1995 he won the Bernard Nicholson Prize in the College exams of the Royal Australasian College of Medical Administrators as the ‘most outstanding candidate’. In November 2009 Dr Goodier was awarded an honorary degree of Doctor of Health Sciences from Anglia Ruskin University.

Gareth returned to the UK as the CEO of the Royal Brompton and Harefield NHS Trust and was later appointed as the CEO of North West London Strategic Health Authority.

In September 2006 he was appointed as the CEO of Cambridge University Hospitals NHS Foundation Trust.

Anil Hansjee

LinkedIn Watch

Anil, investment biker, cordon bleu chef, teaching professor and mentor of digital-age startups, also finds time for a bit of M&A - currently for Google in EMEA. Full profile

Professor Anil Hansjee BSc (Hons) MSc FBCS CITP, joined Google in September 2006 as Head of Corporate Development for Europe, Middle East and Africa, based in London. He is responsible for Google's acquisitions and strategic investments in the region as well as relationships with the early stage technology community and their backers and advisers.

Prior to joining Google, Anil was a Principal with the venture capital firm IDG Ventures, where he was board director of one of their portfolio companies, the mobile music company Shazam Entertainment. Between mid-2000 and the end of 2001, Anil was a Vice President for corporate finance with Bear Stearns International in London. Between mid-1997 and mid-2000, Anil was a member of Chase Manhattan Bank's corporate finance group both in New York and London.  Anil joined Chase's corporate finance team after spending the first seven years of his professional career as a software engineer, first with UBS then Chase. Anil has a BSc (Hons) in Artificial Intelligence and Computer Science from Edinburgh University and an MSc in Finance from London Business School.  He is a Visiting Professor at Kingston University Faculty of Computing, Information Systems and Mathematics.

Anil is a board observer with Google's investments FON (Spain) and Mobile Planet (Kenya). He is also a member of the chartered institute for IT (BCS)’s Policy and Public Affairs Board, an advisory board member of Seedcamp and the European Leadership Programme as well as a member of Sport England's Technology Advisory Board.

Hermann Hauser

Amadeus Capital Partners LinkedIn Watch

Hermann is Cambridge's best-known entrepreneurial venture capitalist. As well as founding Acorn Computers and countless other technology companies, he also co-founded Amadeus Capital Partners. Full profile

In his long and successful history as an entrepreneur and venture capitalist, Hermann has founded or co-founded companies in a wide range of technology sectors. These include Acorn Computers, Active Book Company, Virata, Net Products, NetChannel, and Cambridge Network Limited. He was a founder director of IQ (Bio), IXI Limited, Vocalis, SynGenix, CDT, Electronic Share Information Limited and E*Trade UK.

Hermann co-founded Amadeus Capital Partners in 1997 with Anne Glover and Peter Wynn. At Amadeus, Hermann has acted as non-executive director of many investee companies, including CSR, which provides single chip wireless solutions supporting communications over short-range radio links, and Entropic, a company that developed voice recognition software, which is now the voice recogniser in Microsoft Word. Entropic was sold to Microsoft in 1999. He is currently a non-executive director of Plastic Logic, which has developed a process for producing flexible plastic transistors for use in computer displays, and was a NED of Solexa, which has developed ultra-high throughput DNA sequencing technology.

Hermann holds an MA in Physics from Vienna University and a PhD in Physics from Cambridge University. He is a Fellow of the Institute of Physics and of the Royal Academy of Engineering and an Honorary Fellow of King's College, Cambridge. Hermann holds honorary doctorates from the Universities of Bath, Loughborough and from Anglia Polytechnic, and was awarded an Honorary CBE for innovative service to the UK enterprise sector in 2001. In 2004, he was made a member of the Government’s Council for Science & Technology.

Austrian by birth, Hermann speaks German, English, Italian and French.

Andrew Herbert

Microsoft Research Watch

Managing director of Microsoft Research in Cambridge, Andrew has a long and successful career as an information technology pioneer. He was rewarded for his services to computer science with an OBE in the 2010 honours list. Full profile

Andrew Herbert is a Microsoft distinguished engineer and is the managing director of Microsoft Research in Cambridge, England. Initially joining Microsoft Research in 2001 as an assistant director, in March 2003 he succeeded the founding director, Roger Needham.

Herbert’s research interests include networks, operating systems, programming languages and distributed information sharing.

Before joining Microsoft Research in 2001, he was director of Advanced Technology at Citrix Systems Inc., where he was instrumental in steering the company toward Internet thin-client technologies and initiating development of products for Web-based application deployment and for the emerging application service provider market.

Herbert joined Citrix in 1998 from Digitivity Inc., which he founded in 1996 to develop a product to enable secure deployment of Java clients for business-to-business applications. Digitivity was a spinoff from APM Ltd., a research and consulting company Herbert founded in 1985. APM managed ANSA, an industry-sponsored program of research and advanced development into the use of distributed systems technology to support applications integration in enterprisewide systems. ANSA’s work included research on support for interactive multimedia services, object technology for World Wide Web applications, distributed systems management, mobile object systems and security for electronic commerce. Herbert led ANSA’s technical program, built up its team, created its architecture, and made ANSA known and respected in the industry. ANSA-based technology was used by many organizations ahead of the widespread availability of commercial CORBA-based products. Notable successes included the NASA Astrophysics Data System, a European radio pager system and the online customer service system for a major U.K. utility. As part of his ANSA work, Herbert played an active role in many standards and consortia for distributed computing including the Telecommunications Information Networking Architecture Consortium (TINA-C), ISO/ITU ODP, the Open Software Foundation Distributed Computing Environment (OSF DCE) and Object Management Group (OMG) CORBA.

Before starting ANSA in 1985, Herbert was a faculty member in the Computer Laboratory at the University of Cambridge in England, where he worked with Roger Needham and Maurice Wilkes on seminal developments in local area networks (LANs) and distributed computing. In 1979 Herbert helped Needham and Wilkes edit “The Cambridge CAP Computer and Its Operating System,” and in 1982 he co-authored “The Cambridge Distributed Computing System” with Needham. In 2003, Herbert co-edited a monograph of papers written in tribute to Needham, “Computer Systems: Theory, Technology and Applications,” with Karen Spärck Jones.

In the 2010 honours list Herbert was awarded an Officer of the British Empire (OBE) for services to computer science. He is a fellow of the Royal Academy of Engineering, a fellow of the British Computer Society, a fellow of Wolfson College Cambridge, a visiting professor at University College London, a member of St. John’s College Cambridge, and a liveryman of the City of London Worshipful Company of Information Technologists. In 1975 he graduated from the University of Leeds with a B.Sc. in computational science and in 1978 with a Ph.D. from Cambridge University in computer science.

Alan Hughes

Judge Business School Watch

An optimist by nature, as only a supporter of Sunderland FC can be, Alan is an expert in financing and support mechanisms for technology based start ups, as well as innovation, corporate governance and corporate take-overs, so it’s not surprising that his title at the Judge Business School, University of Cambridge, is “Margaret Thatcher Professor of Enterprise Studies". Full profile

Alan is Director of the Centre for Business Research at the University of Cambridge and of the UK Innovation Research Centre (UK~IRC), a joint venture between Cambridge and Imperial College London. From 2000-2003 he was Co-Director of the National Competitiveness Network of the Cambridge-MIT Institute.

With colleagues at CBR he has pioneered from 1991 onwards the use of regular surveys of the SME sector in the UK. He has published extensively on the results of the regular biennial surveys since then in relation to the financing of SME growth, innovation and SME support policy. He has been involved in a number of evaluations of schemes designed to assist the financing of innovation. He has a long standing research interest in corporate governance and the analysis of corporate takeovers including their impact on innovative performance.

He has published extensively in these areas and on the role of universities in innovation, on the nature of knowledge exchange patterns between universities and the science base, and on the financing of technology based start ups. Work in this area with colleagues at the Centre for Business Research, Cambridge, and at the Industrial Performance Center MIT was published in the report "Cosh, Hughes and Lester (2006) UK PLC: Just How Innovative Are We?".

With PACEC he has recently completed an evaluation of Third Stream Funding for HEFCE. He has also recently completed with colleagues at CBR a 3-year ESRC funded project analysing university-industry links at national and regional levels. This has produced amongst other things a detailed analysis of the involvement of over 22,000 UK academics in commercial and other interactions with the private, public and third sectors.

He has interacted as an adviser on innovation policy in Europe and Australia and to major international organisations. In 2004 he was appointed by the Prime Minister of the UK to membership of the Council for Science and Technology (CST) which is the UK’s senior policy advisory body in this area.

Will Hutton

The Work Foundation Watch

Will Hutton is executive vice chair of The Work Foundation, the most influential voice on work, employment and organisation issues in the UK. Regularly called on to advise senior political and business figures and comment in the national and international media, Will is today one of the pre-eminent economics commentators in the country. Full profile

Will Hutton began his career in the city, as a stockbroker and investment analyst, before moving to the BBC, where he worked both on radio, as a producer and reporter, and on TV as economics correspondent for Newsnight. Prior to joining The Work Foundation, Will spent four years as editor-in-chief of The Observer, for which he continues to write a weekly column. He also regularly contributes to the Guardian and Financial Times.

Will’s best-known book is probably The State We’re In, which was seen at the time as setting the scene for the Blair revolution. Since then he has published The State to Come, The Stakeholding Society, On The Edge (with Anthony Giddens), a groundbreaking analysis of globalisation, and The Writing on the Wall: China and the West in the 21st Century. Will is currently working on his next book – a timely examination of fairness and due desert, Them and Us will be an incisive look at how society has fragmented into inequality, and how to address this most crucial blight on our times.

Outside The Work Foundation, Will is a governor of the London School of Economics, where he is also a visiting professorial fellow at the Centre for Global Governance. He is a member of the Scott Trust, and a fellow of the Sunningdale Institute. In 2004, Will was invited by the European Commission to join a High Level Group on the mid-term review of the Lisbon Strategy and act as its rapporteur for the final report.

In 2009, Will was invited by Business Secretary Lord Mandelson to join a new independent pro-bono advisory panel on New Industry, New Jobs, Universities and Skills, set up to challenge conventional policy thinking in these areas and generate ideas about how to promote the knowledge economy and long-term wealth generation. Most recently, he has agreed to chair the new Commission on Ownership, which will examine to what extent and how ownership matters, ranging from the UK’s market in corporate ownership to the promotion of mutuality in the private and public sector, aiming to deliver their findings in a report to be published in Autumn 2011.

Rob Koepp

Consultant, Financier, and Author LinkedIn Watch

Rob consults, helps fund, and writes about highly creative organizations and the environments in which innovation and entrepreneurship thrive. His first book looked at the Cambridge Phenomenon and its less well-appreciated spinoff, Silicon Valley; his latest looks at how China is overtaking the West with more humane forms of venture capital and private equity finance. Full profile

Rob consults, helps fund, and writes about highly creative organizations and the environments in which innovation and entrepreneurship thrive. His first book looked at the Cambridge Phenomenon and its less well-appreciated spinoff, Silicon Valley; his latest looks at how China is overtaking the West with more humane forms of venture capital and private equity finance.

As a consultant and financial advisor, Rob works with Western and Asian companies on their market development, fundraising, and investment strategies. These range from small ($<5 MM) to large ($100 MM +) transactions and involve companies operating in mass as well as niche markets. Recent projects involve helping spin off a medical device subsidiary from a leading Japanese pharmaceutical company through a leveraged management buyout, devising a unique partnering strategy in China for a major Hollywood animation studio, and raising Series B capital for an FDA-certified organic ingredients manufacturer.

In previous corporate assignments, Rob served as Managing Director of Beijing-based CITIC Rising Star (an entertainment and leisure real estate development subsidiary of the CITIC Group), Operations Manager in Japan for Dresser Industries (a Global 200 energy industry capital equipment supplier and project consultancy); and Engineering and Marketing Manager in Asia for Hitachi High Technologies (a Hitachi Group company and supplier of advanced capital equipment to the global IT and healthcare industries).

In the fields of business and economic thinking, Rob is particularly drawn to the subjects of organizational creativity and knowledge-intensive enterprises. He authored the book Clusters of Creativity: Enduring Lessons on Innovation and Entrepreneurship from Silicon Valley and Europe’s Silicon Fen (John Wiley, 2002), which looks at the underpinning dynamics and key mechanisms of IT and life-science clusters from a global perspective, detailing how high-tech regions and their constituent companies are financed, managed, and generate wealth. Following the success of Clusters, Rob was selected by China’s Ministry of Science and Technology as a report leader in a series of World Bank-sponsored studies on China’s technology park system and reform of China’s national technology industrialization policies.

Rob also completed an English translation of a best-selling Japanese illustrated manga biography on George Soros. He has further written on China’s growing R&D capacity in high tech industries and on reform of China’s financial system. His latest book project is Funded in China: How China Outperforms the West in Financing the Future, scheduled for publication in 2011.

Rob holds a BA in Asian Studies from Pomona College and MBA from the University of Cambridge. A Truman Scholar, he was also awarded a Fellowship from the
Thomas J. Watson Foundation for post-graduate fieldwork in China, Japan, Thailand, Singapore, and Malaysia on the history and evolution of Chinese-based calligraphies. Currently based in Beijing, Rob is fluent in Chinese and Japanese and tries to maintain familiarity with the English language.

Chris Lowe

University of Cambridge Watch

As an academic-entrepreneur, Chris achieves the perfect balance between running one of the leading departments at the University of Cambridge while spinning out a steady flow of successful biotech companies and delivering pragmatic solutions to the problems facing bioscience companies around the world. Full profile

Engineering & Biotechnology at the University of Cambridge. He is a Fellow of Trinity College, the Royal Academy of Engineering, the Institute of Physics and the Royal Society of Chemistry. The Institute of Biotechnology has been awarded a Queen’s Anniversary Prize for Higher and Further Education and Chris received the title of Most Entrepreneurial Scientist of the UK.

The principal focus of his biotechnology research programme over the last 35 years has been the high value - low volume sectors of pharmaceuticals, fine chemicals and diagnostics. The work is characterised by not only being highly inter- and multi-disciplinary and covering aspects of biochemistry, microbiology, chemistry, electrochemistry, physics, electronics, medicine and chemical engineering, but also covering the entire range from pure science to strategic applied science, some of which has significant commercial applications. He has over 320 publications, 8 books and monographs, more than 60 patents and many collaborations worldwide, is an editorial board member of numerous academic journals, a member of research council, grant awarding and government committees, and is active in various legal and entrepreneurial roles. He has supervised over 60 PhD students and won a number of national and international prizes.

He has been the driving force behind the establishment of nine spin-out companies, including ProMetic BioSciences Inc, Purely Proteins Ltd, Affinity Sensors Ltd, Cambridge Sensors Ltd, Smart Holograms Ltd, Psynova Neurotech Ltd, Paramata Ltd, Rebha Ltd and BioJo Ltd.

Mike Lynch

Autonomy Corporation plc Watch

Mike is the founder and CEO of software company Autonomy. The worldwide company currently has a market cap of $6 billion, and is the second largest pure software company in Europe. Full profile

Dr Mike Lynch OBE founded Autonomy Corporation plc in 1996 based on his research at Cambridge University and rapidly established the company's reputation as a world-leading provider of infrastructure software for unstructured information and meaning-based technologies. Covered by over 170 patents, Autonomy’s technology forms a conceptual and contextual understanding from data and enables a host of operations to be automatically performed on emails, websites, phone conversations, video, documents and even people’s interests. It is this unique ability to derive meaning from data that has allowed Autonomy to help over 20,000 organizations around the world harness the true business value of information assets while minimizing the risks endemic to data proliferation.

Over the years Dr Lynch has expanded the Autonomy Group both organically and through a series of targeted acquisitions. With a market capitalization of $6 billion, Autonomy is the UK’s largest software company, a member of the FTSE 100 and was recently awarded the Queen’s Awards for Enterprise: Innovation 2009.
Dr Lynch was named the Confederation of British Industry's Entrepreneur of the Year, the European Business Leaders Awards' Innovator of the Year and Management Today's Entrepreneur of the Year 2009.

He won an IEE Award for Outstanding Achievement and was awarded an OBE for Services to Enterprise. He is also a fellow of the Royal Academy of Engineering, a Lady Margaret Beaufort Fellow of Christ's College, Cambridge, and the author of a number of academic papers on the subject of Pattern Recognition and Signal Processing.

Dr Lynch studied Electrical and Information Sciences at Cambridge University, received a Ph.D. in adaptive techniques in signal processing, and gained a research fellowship in adaptive pattern recognition. He also holds the Institute of Electrical Engineers' medal for outstanding achievement.

Andy Richards

Serial Entrepreneur Watch

A self-confessed biotech addict, Andy Richards is a serial founder and investor in Cambridge life-science companies and an effusive enthusiast for UK Bioscience. Full profile

Dr Andy Richards is a serial Biotechnology entrepreneur and business angel. He is currently Chairman of Altacor, Novacta and Ixico and is a director of Vectura plc, Summit Corp plc, Theradeas, Cancer Research Technology (commercial arm of CR-UK) and Babraham Bioscience Technology.

Andy is a Cambridge graduate with a PhD in Chemistry who spent his early career with ICI (now AstraZeneca) and with PA Technology. He was a founder of Chiroscience and an executive director through to the sale to Celltech in 1999. Since that time he has been founding and investing in new Cambridge based biotechnology companies including several of those listed above as well as Arakis, Geneservice, Cambridge Biotechnology Ltd, Amedis Pharmaceuticals, Sirus Pharmaceuticals, Daniolabs and Pharmakodex, all of which were recently sold.

He is a council member of the Biotechnology and Biological Sciences Research Council (BBSRC), a founder member of the Cambridge Angels, the founding Chairman of BIA Bioangels and an advisor to CUTEC, 4D-biomedical and Toscana Life Sciences.

Dave Roux

Silver Lake Watch

Dave pioneered private equity investing in large scale technology companies. He enjoys working with management teams to help them reach their full potential. Full profile

Dave is a co-founder of Silver Lake and Chairman. He was formerly Chairman and CEO of Liberate Technologies, Executive Vice President at Oracle Corporation and Senior Vice President at Lotus Development. He began his technology career as co-founder and CEO of Datext, Inc., the first commercial CD-ROM publishing company.

Dave is currently Chairman of the Serena Software board and a member of the Avaya and Intelsat boards. Previously, he was a board member of Thomson, Business Objects S.A., Gartner, Inc., Symantec, UGS Corp., and Chairman of the Board of Seagate Technology. He is on the board of the Institute for Health Metrics and Evaluation, a member of the DuBois Institute's National Advisory Board, a trustee at The Center for Advanced Study in the Behavioral Sciences at Stanford University, and an advisor to the Positive Coaching Alliance. Dave holds an MBA from Harvard Business School and an MPhil from Cambridge University. He is a graduate of Harvard College.

Richard Seabrook

The Wellcome Trust Watch

Richard leads the Business Development Team, Technology Transfer Division at The Wellcome Trust. Full profile

Richard leads the Business Development Team, Technology Transfer Division at The Wellcome Trust. The team undertakes due diligence and project management of translation awards, strategic translation awards and seeding drug discovery funding.The Team has responsibility for intellectual property management and its translation such as through licensing or new company formation. Previously, Richard held project management and business development roles in the biotechnology sector and has extensive experience of early-stage funding of life science technologies, commercial transactions, Board, SAB and government agency advisory roles.

Jean Tardy-Joubert

Qatalyst Partners Watch

With an irrepressible spirit, Jean’s passion for technology plays out daily as it has for over 15 years covering the technology industry. Jean joined Qatalyst Partners, a technology-focused independent investment bank with offices in San Francisco and London, in February 2009 to head its European operations. Full profile

Prior to joining Qatalyst Partners, Jean served as head of European Technology Investment Banking at Merrill Lynch, head of the European Technology, Media and Telecom group for Credit Suisse, and head of the European Technology Group for Credit Suisse.

Jean’s clients and transaction experience include IPOs and other financings for ADVA, Alcatel, Alvarion/Floware, Bosch, Cambridge Silicon Radio, CapGemini, ECI Telecom, Ericsson, Marconi, Nokia, NXP/Philips, Psion, Siemens, STMicroelectronics, Tenovis, Virata/Globespan, Vivendi, Wavecom, and Xyratex. He has also advised Alcatel on its $7B acquisition of Newbridge Networks, Floware on its merger with Breezecom, Virata on its merger with Globespan, sale in two transactions of Bosch Telecom to Marconi and KKR, then on its subsequent sale to Avaya, Marconi on its acquisition of Nokia optical transport’s business, the successful hostile defence of Wavecom (merged with Sierra Wireless), advised on the separation of Philip’s semiconductor business (NXP) to a sponsor-led consortium and the respective $6B financing, and the two subsequent disposals of NXP’s C&IPT division to DSP Communications ($270 million) and wireless division to STMicroelectronics ($1.6B), and Siemens AG on its acquisitions of Redstone Communications and Castle Networks.

Jean is originally from Paris, France and graduated in Economics and Finance from Universite Pantheon-Assas (Paris). Jean is fluent in French, English and German.

Anthony Townsend

Institute for the Future Watch

Anthony directs the Institute for the Future's strategic investments in collaborative forecasting platforms, futures media and visualization technologies, and web communications tools. By applying emerging practices like agile development, extreme programming and open data infrastructures to the creation of forecasting tools, he seeks to provide platforms for the Institute to develop rich and wide-reaching forecasting networks. Full profile

Anthony continues to conduct research on the impact of new technology on cities and public institutions. His interests span several inter-related topics: mobility and urbanization, innovation systems and innovation strategy, science and technology parks and economic development, and sustainability and telework.

Anthony believes that foresight can play an important role in shaping public policy, and is involved in policy and planning networks throughout the United States, Europe and Asia. He testified at a United States Senate hearing on "Research Parks and Job Creation" on December 9, 2009, and serves as a member of the National Foreign Trade Council's Global Innovation Forum Brain Trust. He has served on mayoral municipal broadband advisory boards in both New York City and San Francisco.

Before joining IFTF, Anthony enjoyed a brief but productive academic career at New York University, where he directed research sponsored by the National Science Foundation and the Department of Homeland Security. He received a Fulbright scholarship in 2004 to study the social impacts of broadband in South Korea. He was one of the original founders of NYCwireless, a pioneer in the municipal wireless movement that promotes the use of public-access Wi-Fi in the development of local communities.

Anthony holds a Ph.D. in urban and regional planning from Massachusetts Institute of Technology, a master's in urban planning from New York University, and a B.A. in urban studies with a minor in physics from Rutgers University.

John West

ViaCyte Watch

John is a builder of large, market-leading profitable businesses from state-of-the-art scientific advances. During his tenure as CEO of Solexa, the company became public through a reverse merger, raised almost $100M and launched its first commercial product which became the dominant system for genome-scale genetic research. John led the sale of the company in 2007 to Illumina for over $600M. He is now deploying his commercial skills at ViaCyte where he aims to bring stem-cell-derived therapeutics to the market. Full profile

John S. West is ViaCyte's President and Chief Executive Officer.

Mr. West joined Novocell in May 2009 after former CEO Alan Lewis moved on to become President and CEO of the Juvenile Diabetes Research Foundation (JDRF). Previously, Mr. West served as Chief Executive Officer of Solexa, from 2004 until the company's acquisition in 2007. During Mr. West's tenure at Solexa, the company became public through a reverse merger, raised nearly $100M, and launched its first commercial product. This product lowered DNA sequencing costs over 100-fold, achieved almost $100M revenue in its first full year, and became the dominant system for genome-scale genetic research.

Mr. West led the sale of the company to Illumina, Inc. (ILMN) for over $600M, and the business market cap subsequently exceeded $1B. Prior to Solexa, Mr. West served as VP of DNA Platforms, approximately a $1B business, at Applied Biosystems, Inc. (ABI), now Life Technologies. Prior to joining ABI, Mr. West was President of Princeton Instruments, a private company with transformational technology for low light imaging and spectroscopy. The company grew over 10 times in revenue, under the leadership of Mr. West, with much of the growth leveraging advances in cell biology, until it was sold to Roper Industries (NYSE:ROP), where Mr. West continued as subsidiary President.

Mr. West holds B.S. and M.S. degrees in engineering from MIT, and an M.B.A. in finance from the University of Pennsylvania's Wharton School.

Teri Willey

Cambridge Enterprise Watch

Teri joined Cambridge Enterprise (CE) as Chief Executive in 2006. Prior to CE, Teri was a Managing Partner of ARCH Development Partners (ADP), a seed and early stage venture fund focused on university and corporate spin-outs. Full profile

Teri joined Cambridge Enterprise (CE) as Chief Executive in 2006. Prior to CE, Teri was a Managing Partner of ARCH Development Partners (ADP), a seed and early stage venture fund focused on university and corporate spin-outs. Teri, a founder of ADP, participated as a Director on portfolio company, community and venture capital Boards of Directors and Advisory Boards, as a University of Notre Dame Business School Adjunct Professor and continues as an Advisor to ADP.

Prior to the start of ADP, Teri was Vice President of Start-ups at ARCH Development Corporation, a subsidiary of the University of Chicago, which commercialised technology from the University and Argonne National Laboratory. Her experience includes technology transfer roles at Northwestern University, Purdue University and in industry. Teri has been an advisor to policy makers, universities and companies and is a past President of the Association of University Technology Managers (AUTM). Teri is a Bye-Fellow of Christ's College and a Senior Member of Hughes Hall.